Promoted Content
Promoted Content

Find Oncology Drugs in Phase II/III Clinical Development in GERMANY


All Data

Filters Filter refresh
News Type filter
    Company filter
      Product Type filter
        Deal Size filter
          Upfront Payment filter

            Product Type Full Screen

            Companies Full Screen

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Tafasitamab

            Therapeutic Area: Oncology Product Name: Undisclosed

            Highest Development Status: Phase II/ Phase III Product Type: Large molecule

            Partner/Sponsor/Collaborator: Incyte Corporation

            Deal Size: $2,000.0 million Upfront Cash: $750.0 million

            Deal Type: Collaboration January 13, 2020


            MorphoSys and Incyte will co-commercialize tafasitamab in the U.S., while Incyte has exclusive commercialization rights outside of the U.S.